Targeting a specific protein to treat chronic myeloid leukemia
A Leukemia Cell-Specific Coiled-Coil Protein for Treatment of Chronic Myeloid Leukemia
['FUNDING_R01'] · UNIVERSITY OF UTAH · NIH-11001839
This study is testing a new small protein that could help stop a key protein linked to chronic myeloid leukemia from working against you, and if it works, it might offer a fresh treatment option for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-11001839 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a small protein that can inhibit the dimerization of Bcr-Abl, a protein responsible for the majority of chronic myeloid leukemia cases. By preventing Bcr-Abl from dimerizing, the treatment aims to disrupt its oncogenic activity, which is crucial for the progression of the disease. The approach involves using a computationally designed coiled-coil mutant that selectively interacts with Bcr-Abl, potentially offering a new therapeutic strategy. Patients may benefit from this innovative treatment if it proves effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic myeloid leukemia, particularly those with Bcr-Abl positive status.
Not a fit: Patients with other types of leukemia or those without the Bcr-Abl mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with chronic myeloid leukemia.
How similar studies have performed: Other research has shown promise in targeting protein dimerization for cancer treatment, indicating that this approach could be viable.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIM, CAROL S. — UNIVERSITY OF UTAH
- Study coordinator: LIM, CAROL S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.